|Articles|March 8, 2017
Tufts CSDD Releases Results of New Impact Report
A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.
Advertisement
A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Ensuring Digital Trial Platforms Work for Underserved CommunitiesSeptember 10th 2025
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
eClinical Technology: Misconceptions, Challenges, and Opportunities
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
